LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

28.98 0.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.37

Максимум

29.46

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+1.65% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.4B 3.8B
Предишно отваряне	28.88
Предишно затваряне	28.98

Настроения в новините

By Acuity

50%

165 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.12.2025 г., 17:39 ч. UTC

Значими двигатели на пазара

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15.12.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

15.12.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15.12.2025 г., 22:19 ч. UTC

Пазарно говорене

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

15.12.2025 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15.12.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15.12.2025 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15.12.2025 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15.12.2025 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15.12.2025 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Completes Acquisition Of Moveworks >NOW

15.12.2025 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15.12.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15.12.2025 г., 20:36 ч. UTC

Пазарно говорене

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15.12.2025 г., 20:31 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15.12.2025 г., 20:27 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15.12.2025 г., 20:15 ч. UTC

Пазарно говорене

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15.12.2025 г., 19:22 ч. UTC

Пазарно говорене

Gold and Silver Gain to Start Week -- Market Talk

15.12.2025 г., 18:37 ч. UTC

Пазарно говорене

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15.12.2025 г., 18:29 ч. UTC

Пазарно говорене

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15.12.2025 г., 17:58 ч. UTC

Пазарно говорене

Canada Housing Market In Search Of a Bottom -- Market Talk

15.12.2025 г., 17:36 ч. UTC

Пазарно говорене

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15.12.2025 г., 17:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.12.2025 г., 17:36 ч. UTC

Печалби

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15.12.2025 г., 17:30 ч. UTC

Придобивния, сливания и поглъщания

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

1.65% нагоре

12-месечна прогноза

Среден 29.5 USD 1.65%

Висок 37 USD

Нисък 21 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

165 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.